美股异动丨Vir Biotechnology涨超38%创逾一年新高，Q4营收同比暴增417%超预期

Core Viewpoint - Vir Biotechnology's stock surged over 38%, reaching a new high of $10.29, driven by strong quarterly earnings and positive clinical trial results for its treatment candidate VIR-5500 [1] Financial Performance - The company reported fourth-quarter revenue of $64.07 million, a significant increase of 417% year-over-year, surpassing market expectations of $44.16 million [1] - The earnings per share (EPS) loss was $0.31, an improvement from a loss of $0.76 per share in the same quarter last year [1] Clinical Development - Vir Biotechnology announced positive results from the Phase 1 clinical trial of VIR-5500, which is being developed for the treatment of advanced metastatic castration-resistant prostate cancer [1]